Showing results (321-330 of 928) with videos related to

Sort By:
Pageof 93
Psychiatry Research|October 1, 2018
Increased adrenocorticotropic hormone (ACTH) levels predict severity of depression after six months of follow-up in outpatients with major depressive disorderKwan Woo Choi, Eun Jin Na, Maurizio Fava, et al.
The Journal of Asthma : Official Journal of the Association for the Care of Asthma|January 8, 2025
Evaluating the impact of changing inhaler color on perception of symptoms and disease burden in patients with asthma: the FEEL studyFrancesco Blasi, Maria D'Amato, Vincenzo Patella, et al.
European Eating Disorders Review : the Journal of the Eating Disorders Association|September 7, 2023
Pain experience in eating disorders: The mediating role of depression, alexithymia and interoceptive awarenessGilda Fazia, Elvira Anna Carbone, Marianna Rania, et al.
International Clinical Psychopharmacology|September 26, 2009
Discontinuation symptoms and taper/poststudy-emergent adverse events with desvenlafaxine treatment for major depressive disorderStuart A Montgomery, Maurizio Fava, Sudharshan K Padmanabhan, et al.
Comprehensive Psychiatry|February 5, 2008
Validation of the Patient Health Questionnaire-9 for depression screening among Chinese AmericansAlbert Yeung, Freddy Fung, Shu-Ching Yu, et al.
Canadian Journal of Psychiatry. Revue Canadienne De Psychiatrie|July 8, 2005
Ropinirole in treatment-resistant depression: a 16-week pilot studyPaolo Cassano, Lorenzo Lattanzi, Maurizio Fava, et al.
The Journal of Clinical Psychiatry|June 1, 2022
Efficacy and Safety of AXS-05 (Dextromethorphan-Bupropion) in Patients With Major Depressive Disorder: A Phase 3 Randomized Clinical Trial (GEMINI)Dan V Iosifescu, Amanda Jones, Cedric O'Gorman, et al.
International Clinical Psychopharmacology|August 16, 2008
A randomized, double-blind, and placebo-controlled trial of quetiapine augmentation of fluoxetine in major depressive disorderAmir Garakani, Jose M Martinez, Sue Marcus, et al.
Neuropsychobiology|November 27, 2007
Differential antidepressant symptom efficacy: placebo-controlled comparisons of duloxetine and SSRIs (fluoxetine, paroxetine, escitalopram)Craig H Mallinckrodt, Apurva Prakash, John P Houston, et al.
The Journal of Clinical Psychiatry|December 31, 2015
Prevalence and impact of obsessive-compulsive symptoms in depression: a STAR*D reportLee Baer, Madhukar H Trivedi, Ilana Huz, et al.
Pageof 93